BeiGene’s Brukinsa Among Five Orphan Drugs Awaiting EU Approval Verdict

Sponsors Of Two Other Medicines May Have To Address Last-Minute Issues

Sponsors of several new medicines are set to learn if their products are on track for pan-EU approval. One product on the list is Pfizer/Lilly’s osteoarthritis drug, tanezumab, which recently ran into trouble in the US.

Pile of crumpled colorful paper notes with words "Yes" and "No"
It Is Decision Time For Several New Drugs Being Reviewed By The CHMP • Source: Alamy

The European Medicines Agency will decide this week whether to recommend EU-wide approval for a dozen new drugs, including BeiGene’s Brukinsa (zanubrutinib) for treating Waldenström’s macroglobulinemia, and Apellis Pharmaceuticals’ pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria.

Brukinsa and pegcetacoplan are among five orphan medicines that are listed on the agenda of the latest monthly meeting...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet